CWS
NBIX icon

Confluence Wealth Services’s Neurocrine Biosciences NBIX Stock Holding History

Confluence Wealth Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-56
Closed -$4K – 824
2021
Q4 		$4K Buy
+56
New +$5.15K ﹤0.01% 1084

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Confluence Wealth Services's NBIX Position: Q1 2022 in Review

Confluence Wealth Services sold out of Neurocrine Biosciences (NBIX) in Q1 2022, closing a stake of 56 shares — an estimated $4K sold.

Confluence Wealth Services first reported a position in NBIX in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 426 funds tracked by Wall St. Rank hold NBIX as of Q1 2022.

  • Confluence Wealth Services reported no remaining Neurocrine Biosciences position as of Q1 2022 after selling out during the quarter.
  • Confluence Wealth Services sold 56 Neurocrine Biosciences shares in Q1 2022, an estimated $4K.
  • Confluence Wealth Services first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 1 quarter.
  • Confluence Wealth Services's Neurocrine Biosciences position peaked at $4K in Q4 2021.
  • 426 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2022.

Based on Confluence Wealth Services's 13F filing for Q1 2022, filed 26 Apr 2022.